TelyRx Holdings Inc.

As of June 30, 2026, TelyRx Holdings Inc. carries a market capitalization of 63.02M, placing it among publicly traded companies globally. Its enterprise value stands at 51.39M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

TelyRx Holdings Inc.'s next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, TelyRx Holdings Inc. has 26.59M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.46, and the price-to-book ratio stands at 4.07.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 51.39M versus a market cap of 63.02M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, TelyRx Holdings Inc. maintains a current ratio of 3.46, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 123.64, indicating elevated leverage, while an interest coverage ratio of -7.84 demonstrates limited ability to service its debt obligations.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, TelyRx Holdings Inc. generated 97.52M in revenue and converted that into -18.88M in net income, yielding earnings per share of -0.99. EBITDA reached -7.48M, while operating income came in at -17.16M.

As of June 30, 2026, TelyRx Holdings Inc. holds 30.76M in cash and equivalents against 19.14M in total debt, resulting in a net debt position of -16.36M. Total book value stands at 15.48M, with working capital of 25.73M providing operational flexibility.

TelyRx Holdings Inc. produced -8.82M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.97M in capital expenditures, free cash flow totaled -10.80M - equivalent to -0.57 per share.

Over the twelve months ended June 30, 2026, TelyRx Holdings Inc. posted a gross margin of 55.97, reflecting its pricing power and cost economics. The operating margin of -17.59 and net profit margin of -19.36 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -23.90: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -58.96, meaning TelyRx Holdings Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

TelyRx Holdings Inc.'s most recent stock split took place on April 7, 2026 with a 30:1 split ratio.

As of June 30, 2026, TelyRx Holdings Inc. has an Altman Z-Score of 1.46, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.